OX124 enters pivotal study
Orexo has successfully initiated the pivotal trial OX124-002 for its lead pharmaceutical pipeline asset, OX124. The first cohort of healthy volunteers has been dosed on July 15, 2021.
In our efforts to address unmet needs Orexo develops improved specialty pharma treatments by combining known pharmaceutical substances with its patented proprietary drug delivery technologies. The development process is characterized by lower risk and shorter time to market.
Since its inception, Orexo has developed three pharmaceutical products that are commercialized by Orexo in the US or worldwide through partners. These products have been developed with a focus on innovative solutions to address patient need, mostly within opioid addiction and pain. Today, Orexo is a well-established business with the financial resources and expertise to drive projects from concept to commercialization.
Pipeline of pharmaceuticals and development projects
Pharmaceuticals
Product/Project
Exploratory
Preclinical
Phase
1
2
3
Registration
Approved and/or Launched
US
EU
RoW
ZUBSOLV® Opioid Use Disorder
Abstral® Breakthrough Cancer Pain
Partner: Kyowa Kirin
Partner: Kyowa Kirin
Edluar® Insomnia
Partner: Mylan
Partner: Mylan
OX124 Naloxone, Opioid Overdose
OX125 Nalmefen, Opioid Overdose
OX338 Ketorolac, Moderate to moderately severe pain
OX640 Adrenaline. Nasal adrenaline medication
OX-MPI BI1029539, microvascular Disease
Partner: Gesynta Pharma
Partner: Gesynta Pharma
Approved in Australia
Next generation technologies
One aim is to develop innovative technologies for both oral, sublingual and intranasal drug formulations. Several important steps have been taken to develop platforms for new products that can benefit patients worldwide.